Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 14, 2020
Reporting Period: Specific event date (December 14, 2020)
Business Context: The filing discloses the entry into a material definitive agreement regarding the appointment of a new executive officer.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing focuses exclusively on a personnel agreement.
Material Changes
Executive Appointment: Effective December 14, 2020, the Company appointed Dr. Jack Reich as Head of Regulatory.
Compensation Terms:
- Base Salary: $225,000 per year.
- Annual Bonus: Target of 30% of base salary, subject to Board discretion.
- Reporting Line: Reports directly to the Chief Executive Officer.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks or contingencies beyond the standard incorporation of the Offer Letter by reference. No unusual items were reported.
Investor Verification Checklist
- Verify the full terms of the Offer Letter filed as Exhibit 10.1, as the summary in the 8-K is not complete.
- Confirm Dr. Jack Reich's start date and any additional equity or benefit provisions not detailed in the summary.
- Review the Company's cash position in recent 10-Q or 10-K filings to assess the impact of the new salary obligation.